GlassScriptPhysician profile
Roberto G Pabalate
NPI 1528221504
$1,771.72
in general payments reported to CMS, 2019-2025
20 companies · $17.82 in 2025
The $17.82 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $508 · 2021: $67.63 · 2022: $122 · 2025: $17.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $199.75 | 2019-2020 | |
| Pfizer INC. | $195.15 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $170.52 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.44 | 2019-2020 | |
| Lilly USA, LLC | $142.44 | 2019-2020 | |
| Insulet Corporation | $141.88 | 2019-2022 | |
| Abbott Laboratories | $111.83 | 2020-2025 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $111.62 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $95.65 | 2019-2020 | |
| Novo Nordisk INC | $68.23 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $58.55 | 2019 | |
| Allergan, INC. | $50.05 | 2020 | |
| Merck Sharp & Dohme LLC | $46.30 | 2019-2020 | |
| Abbvie INC. | $42.47 | 2021-2022 | |
| Amgen INC. | $39.40 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $36.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.93 | 2019-2020 | |
| Valeritas, INC. | $23.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.77 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Pabalate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.